MilliporeSigma announces $65-million manufacturing expansion in Wisconsin
MilliporeSigma (Burlington, Mass.) announced a $65 million expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its facility near Madison, Wisconsin. This investment will allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.

MilliporeSigma’s new 70,000-square-foot commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifically designed to handle single-digit nanogram occupational exposure limit materials. The facility will incorporate containment areas to produce next-generation linker and payload materials for ADCs. The project is an addition to the company’s Madison campus, which was the first commercial ADC facility in North America designed to handle highly active materials. It will join MilliporeSigma’s established campus in St. Louis, Missouri, which specializes in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing...
   ...more

Ken Notes: They win my award for most psychedelic logo hands down! I am guessing this will happen at the Verona location....



- - Volume: 8 - WEEK: 37 Date: 9/10/2020 9:41:46 AM -